skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

In June 2016, all United Nations Member States pledged to end the AIDS epidemic as a public health threat by 2030 and signed up to time-bound targets. These targets included reducing the number of people newly infected with HIV from 2.1 million in 2015, to fewer than 500,000 in 2020 and reducing the number of people dying from AIDS-related illnesses from 1.1 million in 2015, to fewer than 500,000 in 2020 [1]. These aggressive targets will only be possible with a holistic approach to both treatment and prevention of HIV infection. Effective antiretroviral drugs for the treatment of HIV had been approved for a number of years, however, despite initially promising vaccine candidates, a pharmacological approach to prophylaxis remained elusive. The approval of Truvada for HIV pre-exposure prophylaxis (PrEP) in 2012 changed this. The interactive infographic below charts the changing HIV prophylaxis trial landscape leading up to and following this key milestone.

[1] United Nations Sustainable Development Goals (June 2016) Bold new Political Declaration on Ending AIDS adopted in New York; Available from: [Accessed February 2019]


Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: